Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns
- PMID: 9502078
- DOI: 10.1023/a:1006564002679
Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns
Abstract
Expression of proteolytic parameters of the urokinase-type plasminogen activator (uPA) system [uPA receptor (uPA-R), plasminogen activator inhibitor (PAI)-1] has been proven to be an independent prognostic parameter in cancer. However, it has not been considered that the uPA system is interacting with several other protease/inhibitor systems, neither has a comparable prognostic role of these factors been investigated. Moreover, studies evaluating specific protease patterns indicating high individual risk are missing completely. Therefore, in a consecutive prospective series of 203 gastric cancer patients, the expression of activators (plasminogen, tPA, MMP-2, cathepsin D, antithrombin 3) and inhibitors (alpha-2-antiplasmin, alpha-2-macroglobulin, alpha-1-antitrypsin, alpha-1-antichymotrypsin) of proteolysis was studied immunohistochemically in the tumor epithelium semiquantitatively (score 0-3) in addition to the uPA system. Kaplan-Meier analysis (median time of follow-up 31 months) revealed a significant association of cathepsin D (P=0.0042), alpha-2-macroglobulin (P=0.0281) and antitrypsin (P=0.0372) with disease-free survival and of cathepsin D (P=0.0018), antitrypsin (P=0.0112) and antichymotrypsin (P=0.0002) with overall survival. Multivariate Cox analysis performed to correct these results for relative impact of the uPA system and established prognostic factors showed PAI-1 (disease-free survival: P=0.002, relative risk 1.86; overall survival: P=0.005, relative risk 1.39), pT and pN as independent parameters. Cathepsin D was shown to have an independent impact on disease-free survival (P=0.020, relative risk 2.98). Comparative chi-square analysis of cases with poor and good prognoses revealed that in patients with good clinical outcome, inhibitors of proteolysis are correlated significantly, whereas in patients with poor prognosis activators of proteolysis are significantly associated preferentially and significant correlations with the uPA-R are dominant. For detailed pattern analysis, stepwise overall Kaplan-Meier analyses were performed in subgroups of high uPA-R-, uPA-, PAI1- and cathepsin D expression for two additional proteases each. From these analyses, the combination of high (score 2/3) expression of uPA-R, PAI-1, antichymotrypsin and alpha-2-macroglobulin was identified as a high-risk pattern, representing parameters known to be essential for uPA-R internalization and recycling. This suggests some of the uPA-associated proteases and inhibitors investigated as univariate prognostic parameters in gastric cancer. Cathepsin D is a new independent parameter for disease-free survival. The study further demonstrates that a protease pattern promoting uPA-R recycling in tumor cells especially indicates high individual risk tumors in gastric cancer.
Similar articles
-
Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.Ann Surg. 1997 Dec;226(6):736-44; discussion 744-5. doi: 10.1097/00000658-199712000-00010. Ann Surg. 1997. PMID: 9409572 Free PMC article.
-
c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.J Clin Oncol. 2000 Jun;18(11):2201-9. doi: 10.1200/JCO.2000.18.11.2201. J Clin Oncol. 2000. PMID: 10829039
-
An immunohistochemical assessment of cathepsin D in gastric carcinoma: its impact on clinical prognosis.Cancer. 1997 Jul 15;80(2):179-87. doi: 10.1002/(sici)1097-0142(19970715)80:2<179::aid-cncr2>3.0.co;2-p. Cancer. 1997. PMID: 9217027
-
[The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer].Orv Hetil. 1999 Aug 15;140(33):1833-6. Orv Hetil. 1999. PMID: 10489782 Review. Hungarian.
-
Neutral proteinases and their inhibitors in the loosening of total hip prostheses.Acta Orthop Scand Suppl. 1996 Oct;271:3-29. Acta Orthop Scand Suppl. 1996. PMID: 8975533 Review.
Cited by
-
Expression of the serine protease inhibitor serpinA3 in human colorectal adenocarcinomas.Oncol Lett. 2011 May;2(3):413-418. doi: 10.3892/ol.2011.280. Epub 2011 Mar 21. Oncol Lett. 2011. PMID: 22866096 Free PMC article.
-
Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer.J Gastroenterol. 2007 Feb;42(2):120-8. doi: 10.1007/s00535-006-1975-y. Epub 2007 Mar 12. J Gastroenterol. 2007. PMID: 17351800
-
Protease inhibitor SERPINA1 expression in epithelial ovarian cancer.Clin Exp Metastasis. 2010;27(1):55-69. doi: 10.1007/s10585-009-9303-6. Epub 2010 Jan 5. Clin Exp Metastasis. 2010. PMID: 20049513
-
Using Comparative Proteomics to Identify Protein Signatures in Clear Cell Renal Cell Carcinoma.Cancer Genomics Proteomics. 2023 Nov-Dec;20(6):592-601. doi: 10.21873/cgp.20408. Cancer Genomics Proteomics. 2023. PMID: 37889066 Free PMC article.
-
S-glutathionylated serine proteinase inhibitors as plasma biomarkers in assessing response to redox-modulating drugs.Cancer Res. 2012 May 1;72(9):2383-93. doi: 10.1158/0008-5472.CAN-11-4088. Epub 2012 Mar 8. Cancer Res. 2012. PMID: 22406622 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous